Antibodies that bind the Type I insulin-like growth factor receptor (IGF-1R), and prevent ligand association, have been tested in numerous clinical trials. Despite compelling data to indicate the importance of IGF-1R-mediated signaling particularly in sarcoma cells, these antibodies have rarely induced objective tumor regressions either in sarcoma patients or in preclinical xenograft models of sarcoma. Our data suggest that IGF-1R-targeted antibodies are potent antiangiogenic agents. However, tumor-derived IGF-2 circumvents the IGF-1R antibodies, signaling through the insulin receptor (IR). In contrast, antibodies that bind IGF ligands inhibit IGF-2 stimulated proliferation of human vascular endothelial cells, but the effect is reversed by exogenous IGF-1.
INTRODUCTION
Many human cancers, including childhood sarcomas, exhibit autocrine or paracrine growth through secretion of insulin-like growth factors 1 and 2 (IGF-1, IGF-2) and signaling through the Type 1 receptor (IGF-1R) (1, 2) . IGF-1R is a receptor tyrosine kinase that is widely expressed in multiple human cancers and is activated by its related ligands, IGF-1 and IGF-2. This interaction activates intrinsic tyrosine kinase activity, resulting in receptor auto phosphorylation and stimulation of signaling cascades that include the IRS-1/PI-3K/AKT/mTOR, and Grb2/Sos/Ras/MAPK pathways (3) . Dysregulation of insulin-like growth factors (IGFs) has been associated with the pathogenesis of various pediatric cancers, such as osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma, thereby providing a potential therapeutic target for the treatment of these tumors. (4) . In preclinical models of childhood cancers, the prototypical anti-IGF-1R antibody, α-IR3, mediated down regulation of IGF-IR, significantly retarded growth of several cell lines in vitro (5, 6) , and inhibited the growth of rhabdomyosarcoma xenografts (7) .
IGF-1R and its ligands play roles not only in tumor cell proliferation and survival, but also in tumor angiogenesis (8) . Two studies have suggested that IGF-1R antibodies exert a strong effect on tumor angiogenesis (6, 9) . Our data showed anti-angiogenic activity of IGF-1R-binding antibody (SCH717454) both in vitro and in vivo but IGF-2 circumvented these effects (10) . Many childhood cancers secrete IGF-2, suggesting that tumor-derived IGF-2 can promote angiogenesis in the presence of IGF-1R-targeted antibodies through binding to the insulin receptor (IR) permitting continued tumor growth. Several studies have reported overexpression of IGF2 in sarcoma cell lines as well as in primary tumors (5, (11) (12) (13) .
Currently there are both small molecule drugs and fully human or humanized antibodies directed at the IGF-1R. Five fully human (CP-751871, AMG 479, R1507, IMC-A12, SCH717454) or humanized antibodies (H7C10/MK0646) have been evaluated in adult phase-I to -III clinical trials. These agents show specificity for IGF-IR although they may inhibit chimeric receptors formed through hetero-dimerization with the insulin receptor (IR). However, in xenograft models of childhood tumors associated with IGF-dysregulation, these antibodies induce only rare tumor regressions (6, 14, 15) , consistent with the relatively low response rate of Ewing sarcoma patients to figitumumab (CP751871) (16) .Intrinsic resistance may be a consequence of maintained signaling by IGF-2 through the IR (8, 10, 17, 18) . The aim of this study was to evaluate the anti-angiogenic activity of an IGF-ligand binding antibody (MEDI-573) alone, or combined with IGF-1R receptor-binding antibodies. This is the first report showing the anti-angiogenic activity of the ligand-neutralizing antibody MEDI-573, and reversal of activity by exogenous IGF-1. Our results also demonstrate that, both in vitro and in a mouse model, combined inhibition of IGF-1R and its ligands (IGF1/2) abrogates angiogenesis in the presence of exogenous IGF's. Targeting angiogenesis by inhibiting both IGF-1R and IGFs through use of dual antibodies may therefore be an effective anti-angiogenic strategy in pediatric sarcomas.
Research. Matrigel inserts for invasion assays were purchased from BD Biosciences (Palo Alto, CA).
MedImmune generously provided MEDI-573 and CP1-B02 antibodies and MAB391 antibody was purchased from R&D Systems. MEDI-573 binds human IGF-2 with high affinity, while its affinity for human IGF-1 is lower, and affinity for murine IGF-1 is very low (19) . CP1-B02 and MAB391 antibodies bind the IGF-1 receptor, preventing ligand binding. Human recombinant IGF-1 and IGF-2 were purchased from PeproTech Inc., NJ. BMS754807 was purchased through Selleckchem.com.
Cell Culture. Human umbilical vein endothelial cells (HUVEC) were obtained from the American
Type Culture Collection (ATCC). All experiments were done using endothelial cells between passages 3 and 8. HUVECs were maintained in medium M200 (Invitrogen) with 15% fetal bovine serum (FBS), endothelial cell growth supplements (LSGS Medium, Cascade Biologics), and 2 mM glutamine at 37°C with 5% CO 2 . All cells were maintained as sub confluent cultures and split 1:3, 24 hr before use. Rhabdomyosarcoma cell lines were cultured in RPMI 1640 supplemented with 10% FBS.
Western blotting. Cell lysis, protein extraction and immunoblotting were as described previously (6, 9) . We used primary antibodies to glyceraldehyde-3-phosphate dehydrogenase at 58°C, 60 s at 72°C and a final extension for 10 min at 72°C. PCR products were identified using electrophoresis on 1.5% agarose gels containing ethidium bromide (Et-Br). Statistics: Two-sample t-tests were used for the analysis of the experiments with continues outcomes using GraphPad Prism. Data were reported as mean ± SE. Type I error rate was set to 0.05. For in vivo testing against pediatric sarcoma xenograft models, criteria for defining an event (4 times the tumor volume at the start of treatment) was similar to that used by the PPTP (20) . Log-rank tests were used to compare the time-to-event curves between groups and Holm's method was used to adjust multiplicity within each xenograft model. SAS 9.3 was used for this analysis (SAS, Inc; Cary, NC).
Endothelial
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RESULTS

Effect of antibodies on ligand induced IGF-1R signaling
MEDI-573 potently inhibits angiogenesis by blocking HUVEC tube formation and proliferation in vitro.
We next examined whether MEDI-573 inhibited VEGF 165 induced tube formation of HUVECs, focusing on an antibody concentration range of 10 to 30 μg/ml. HUVECs were stimulated with VEGF 165 (10 ng/mL) on Matrigel to form tubes in the absence or presence of MEDI-573 ( Figure   2A ). Reduction in tube formation by MEDI-573 was concentration-dependent; at 30 μg/ml the antibody significantly inhibited tube formation. For the proliferation assay HUVEC cells were stimulated with VEGF 165 in the absence or presence of MEDI-573 and cell number determined by Calcein AB staining after 4 days. As shown in Figure 2B . MEDI-573 inhibited proliferation in a concentration-dependent manner with >70% inhibition at 30 μg/ml. An isotype matched (IgG2λ) control antibody had no effect on either tube formation of cell proliferation (data not shown).
MAB391 potently inhibit angiogenesis in vitro
Previous studies (6, 9, 10) have shown that IGF-1R-targeted antibodies exert anti-angiogenic effects, and that IGF-1R signaling is required for HUVEC proliferation when stimulated by VEGF (10) . Results using MAB391 are consistent with these data, and show that MAB391 inhibits VEGF-stimulated tube formation of HUVECs in vitro at 15 μg/ml (Figure 2C ).
Anti-angiogenic activity of MEDI-573 in vivo
IGF-1 circumvents the anti-angiogenic activity of MEDI-573 in vitro
To ascertain why MEDI-573 failed to inhibit angiogenesis in the Matrigel plugs, we further examined its activity in vitro. While MEDI-573 is a dual IGF-1/IGF-2-neutralizing antibody, it binds IGF-1 with a lower affinity compared to its affinity for IGF2. Furthermore, the affinity of MEDI-573 for murine IGF-1 is far lower than that for human IGF-1 (19) . Figure 3A , VEGF stimulated tube formation was completely inhibited by MEDI-573. Exogenous IGF-2 (50 ng/ml) did not significantly overcome the effect of MEDI-573, whereas IGF-1 (10 ng/ml) partially circumvented the blockade.
IGF-2 circumvents the anti-angiogenic activity of MAB391 in vitro
Our previous results (10) showed that cells secreting IGF-2 could maintain angiogenesis in the presence of IGF-1R-targeted antibodies, whereas those secreting predominantly IGF-1 could not. We therefore tested whether exogenous IGF-1/2 could circumvent the MAB391 induced block of VEGF-induced tube formation of HUVECs. Cells were grown under serum-depleted conditions with PBS (control), or VEGF without and with MAB391, or with VEGF, antibody and exogenous IGFs. As shown in Figure 3B , VEGF stimulated tube formation was completely inhibited by MAB391. Exogenous IGF-1 did not significantly overcome the effect of MAB391, whereas IGF-2 circumvented the blockade.
Effect of the combined of receptor binding and ligand binding antibodies on HUVEC tube
Research. Characterization of CP1-B02 showed that it was similar to MAB391 (or SCH717454) in that it blocked IGF-1 stimulation of Akt phosphorylation, but not that induced by IGF-2, and potently blocked HUVEC tube formation and proliferation (Supplemental Figures 2-4) . For in vivo evaluation, Matrigel plugs infused with PBS (control), VEGF (100 ng/ml), or VEGF+IGF-2 (50 ng/ml) were implanted subcutaneously. Mice received two administrations of MEDI-573, CP1-B02 or the combination of antibodies, and angiogenesis was determined on day 7, as described above. As shown in Figure 5B , CP1-B02 blocked VEGF-stimulated angiogenesis, whereas MEDI-573 did not. The combination of antibodies blocked VEGF stimulated angiogenesis, as anticipated, but also suppressed angiogenesis into Matrigel plugs containing both VEGF and IGF-2.
Effect of the combined of receptor binding and ligand binding antibodies on growth of IGF-secreting pediatric sarcoma xenografts
The antitumor activity of CP01-B02, MEDI-573 or the combination was evaluated against four pediatric sarcoma models. Ewing sarcoma lines (EW-5, EW-8) secrete predominantly IGF-1, whereas rhabdomyosarcoma lines (Rh18, Rh30) secrete predominantly IGF-2 (6). MEDI-573 or CP01-B)2 failed to significantly inhibit tumor growth of any model (p=0.784-1.00). In contrast, combined therapy with CP01-B02 plus MEDI-573 was significantly more effective than either single antibody treatment (p= 0.048 -<0.0001), Figure 6A and Supplemental Table 1 . stimulated with VEGF165 in the absence or presence of MAB391 (15 μg/ml), or antibody plus IGF-1 (10 ng/ml) or IGF-2 (50 ng/ml). Tube formation was quantified as described in Materials and Methods. Each result is the mean ± SE for 3 independent experiments. or MEDI-573 with MAB391 and both IGF-1 and IGF-2. Tube formation was quantified as described in Materials and Methods. Each result is the mean ± SE for 3 independent experiments .B. Matrigel plugs containing with PBS, VEGF (100 ng/ml) or VEGF (100 ng/ml) plus IGF-2 (50 ng/ml) were implanted subcutaneously in mice. Mice received no treatment, MEDI-573 (30 mg/kg), CP1-B02 (C (20 mg/kg) or both antibodies on day 0 (after Matrigel plug implantation) and day 3. The Matrigel plugs were excised on day 7, and processed as described in the legend to Figure 3 (Mean ± SE from 6 high-power fields). harvested at 'event' (4-fold tumor volume at treatment initiation), and stained for CD34 to determine tumor microvessels, and Ki67 to assess proliferation.
